Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 18Terminated 3Recruiting 2Active not recruiting 2Unknown 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 22Pancreatic Neoplasms 16Neoplasm Metastasis 9Rectal Neoplasms 5Neuroblastoma 5Neoplasms 5Colonic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Rhabdomyosarcoma 4Lung Neoplasms 4Sarcoma, Ewing 3Cholangiocarcinoma 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Medulloblastoma 2Hepatoblastoma 2Glioma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bone Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Cancer 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1

Interventions

Oxaliplatin 8Fluorouracil 8Leucovorin 7Paclitaxel 5pembrolizumab 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2Docetaxel 2Carboplatin 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × Irinotecan × Clear all
NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06356311 2026-02-27

TroFuse-015

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡